Is Myocardial Infarction in Patients without Significant Stenosis on a Coronary Angiogram as Benign as Believed?
Shi Hyun Rhew, Youngkeun Ahn*, Min Chul Kim, Su Young Jang, Kyung Hoon Cho, Seung Hwan Hwang, Min Goo Lee, Jum Suk Ko, Keun Ho Park, Doo Sun Sim, Nam Sik Yoon, Hyun Ju Yoon, Kye Hun Kim, Young Joon Hong, Hyung Wook Park, Ju Han Kim, Myung Ho Jeong, Jeong Gwan Cho, Jong Chun Park and Jung Chaee Kang

Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea

The present study aimed to investigate the clinical characteristics and 1-year outcomes of acute myocardial infarction (AMI) patients without significant stenosis on a coronary angiogram comparison with the clinical characteristics and outcomes of patients with significant coronary artery stenosis. A total of 1,220 patients with AMI were retrospectively classified into Group I (≥ 50% diameter stenosis, n=1,120) and Group II (< 50%, n=100). Group II was further divided into two subgroups according to the underlying etiology: cryptogenic (Group II-a, n=54) and those with possible causative factors (Group II-b, n=46). Patients in Group II were younger, were more likely to be women, and were less likely to smoke and to have diabetes mellitus than were patients in Group I. The levels of cardiac enzymes, LDL-cholesterol levels, and the apo-B/A1 ratio were lower in Group II. However, 1-month and 12-month rates of major adverse cardiac events (MACE) were not significantly different between the two groups. The Group II-b subgroup comprised 29 patients with vasospasm, 11 with myocardial bridge, and 6 with spontaneous thrombolysis. Left ventricular ejection fraction and creatinine clearance were lower and levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hs-CRP) were higher in Group II-a than in Group II-b. However, outcomes including MACE and mortality at 12 months were not significantly different between the two subgroups. The 1-year outcomes of patients in Group II were similar to those of patients in Group I. The clinical outcomes in Group II-a were also similar to those of Group II-b, although the former group showed higher levels of NT-proBNP and hs-CRP.

Key Words: Coronary angiography; Myocardial infarction; Stenosis

INTRODUCTION

Acute myocardial infarction (AMI) typically results from critical coronary occlusive diseases or a total coronary occlusion after acute plaque rupture.1 Myocardial infarction with angiographically near-normal coronary arteries (MINC) is a multifactorial syndrome for which the exact cause often remains undetermined in individual patients.2-4 Disparate etiologic factors have been incriminated in MINC, i.e., transient occlusion of the infarct-related artery owing to platelet hyperactivity and thrombosis (hypercoagulability),5-7 coronary artery spasm,8 coronary embolism,9,10 and coronary abnormalities such as myocardial bridges, coronary ectasia, or coronary dissection.11

Whereas the overall prevalence rate of MINC ranges from 1% to 12% depending on the definition,12 its prognosis may vary according to the underlying causes and its definition. The majority of previous studies have shown that the prognosis of MINC is better than that of significant coronary stenosis (MICAS).13-17 However, a recent study showed similar prognosis between patients with MINC.
and those with one- or two-vessel diseased MICAS. Moreover, MINC patients have a substantial risk of subsequent coronary events within the first year. The present study was aimed to examine the clinical characteristics and outcomes of MINC patients compared with those of MICAS patients.

MATERIALS AND METHODS

1. Data collection

The study protocol was approved by the ethics committee of the Chonnam National University Hospital. Patients admitted with AMI during the period from January 2006 to December 2008 were retrospectively analyzed. The following criteria had to be met for inclusion in the study: 1) satisfied the criteria for AMI as described in the definition section, 2) no prior history of significant coronary artery stenosis as determined by coronary angiography, and 3) cardiac catheterization and coronary angiography performed during admission. Patients who underwent primary thrombolysis were excluded from the study. Patients were classified into two groups according to the presence or absence of significant coronary artery stenosis as follows: Group I (≥50% diameter stenosis, n=1,120) and Group II (<50%, n=100). Clinical characteristics and 1-month and 12-month major adverse cardiac events (MACE) were reviewed. Patient records were assiduously searched for information on possible etiologic factors, including coronary spasm, myocardial bridge, and spontaneous thrombosis. Group II was then subdivided into two according to the presence or absence of possible underlying etiology as evidenced by angiography: Group II-a (cryptogenic) and Group II-b (associated with possible causative factors such as vasospasm, myocardial bridge, or spontaneous thrombosis).

The patient characteristics reviewed included their medical history (diabetes mellitus, hypertension, smoking, dyslipidemia, prior AMI, prior angina, prior coronary artery bypass graft, prior percutaneous coronary intervention, and family history), presentation characteristics (systolic blood pressure (SBP) and heart rate), diagnostic electrocardiography (ECG) (ST-segment elevation or depression, Q-wave, T-wave change, and new onset left bundle branch block), laboratory findings (glucose, creatinine clearance, cardiac enzymes, serum cholesterol, high-sensitivity C-reactive protein (hs-CRP), and N-terminal pro-brain natriuretic peptide (NT-proBNP), and echocardiographic findings [left ventricle ejection fraction (LVEF) <45%], and medications at hospital discharge. Blood samples were drawn during admission with overnight fasting for fasting blood sugar and blood lipid measurements. Clinical, angiographic, and in-hospital outcome data were retrospectively collected by a nurse or research coordinator. Follow-up and outcome data were retrieved from the hospital database and by telephoning the patients or their next of kin with respect to adverse cardiac events, such as death, angina, reinfarction, and heart failure symptoms.

2. Definitions

The diagnosis of myocardial infarction was primarily based on the detection of a rise or fall in cardiac biomarkers (preferably troponin) with at least one value above the 99th percentile of the upper reference limit together with evidence of myocardial ischemia with at least one of the following: symptoms of ischemia, ECG changes indicative of new ischemia (new ST-T changes or new left bundle branch block, development of pathologic Q wave). Coronary stenosis was considered significant if it exceeded 50% in one of the three main epicardial vessels or the left coronary artery. Patients without significant stenosis (Group II) were subgrouped into two; those not having possible etiology of AMI (cryptogenic, Group II-a) and those having possible etiology (Group II-b). The etiologies identified by angiography were coronary spasm, spontaneous thrombolysis, and myocardial bridge. Coronary spasm was defined if the result of a ergonovine test was positive or if generalized spastic vessel was relieved by intracoronary nitroglycerin injection; spontaneous thrombolysis was defined if a thrombotic process had already been resolved when catheterization was being done and thus only remnant thrombi were detected on coronary angiography; and myocardial bridge was defined as coronary stenosis more than 50% in the systolic period. Hypertension was diagnosed if the patient had a history of hypertension with ongoing treatment or the admission blood pressure was equal to or greater than 140/90 mmHg; diabetes was diagnosed if fasting serum glucose was greater than 126 mg/dl or diabetes medication was actively utilized. MACE included death and reinfarction.

3. Coronary angiography

Conventional coronary angiography was performed in a standard manner. Standard multiple projections were recorded for the left and right coronary arteries. Following the insertion of the arterial sheath, heparin was administered at the beginning of the procedure. All patients were treated with 300 mg aspirin and were loaded with 300 or 600 mg clopidogrel before coronary angiography, unless contraindicated. Percutaneous coronary intervention was performed by a standard technique through the femoral approach in most cases. Use of stents and adjunctive devices was determined on the basis of individual physician assessments.

4. Statistical analysis

Statistical analysis was performed using SPSS software, version 17.0. Continuous variables were reported as the mean ± standard deviation (SD) and were compared by using the Mann-Whitney U test or the Student’s t test. Categorical variables were compared by using the chi-square test or Fisher’s exact test. A multivariate logis-
tic regression analysis was performed to evaluate predictors for 1-year MACE in combined Group I and Group II patients. Subgroup analysis in Group II was performed to evaluate differences in risk factors and incidence of MACE according to the underlying etiology (Group II-a vs. II-b). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Kaplan-Meier analysis was used to create freedom-from-event survival curves for MACE, and the log-rank test was used for their comparison. A p value < 0.05 was considered statistically significant.

RESULTS

After screening the angiographic data for the 1220 patients presenting with AMI, a total of 100 consecutive patients (59 men and 41 women) fulfilled the angiographic criteria and were included in the final analysis of Group II. Group I comprised 1120 consecutive patients with AMI resulting from CAD who were identified during the same time period. Of 1120 patients in Group II, 662 (59.1%) received percutaneous coronary intervention, 444 (39.6%) received medical treatment, and 19 (1.6%) underwent coronary artery bypass grafting as the main treatment strategy within 1 year.

1. Clinical characteristics and laboratory findings

The clinical characteristics are described in Table 1. Group II was younger than Group I (58.5±14.2 vs. 63.4±12.2 years, p=0.001) and included more females (41.0% vs. 28.9%, p=0.008). Group II patients had a lower prevalence of cardiovascular disease risk factors (diabetes mellitus, p=0.001; history of smoking, p=0.005), except for a higher prevalence of a family history of cardiovascular disease. Although a trend toward a lower prevalence of hyperlipidemia was apparent in Group II patients, the difference was not statistically significant. The two groups did not differ significantly with respect to SBP, LVEF, prevalence of hypertension, or body mass index.

The laboratory findings are described in Table 2. Group II had a higher creatinine clearance rate and lower mean creatine kinase, cardiac enzymes [muscle brain isoenzyme of creatine kinase (CK-MB) and troponin I], low density lipoprotein (LDL)-cholesterol, and apo-B/A1 ratio than did Group I. Blood glucose, total and high-density lipoprotein (HDL)-cholesterol, hs-CRP, NT-proBNP, and Lp (a) levels did not differ significantly between the groups.

2. Etiologic factors related to AMI in Group II

Of the 100 patients (Group II screened), 46 patients (Group II-b) had secondary etiologic factors. A coronary spasm was documented in 29 (29%), myocardial bridge in 11 (11%), and spontaneous thrombolysis in 6 (6%), whereas etiologic factors were not found in the remaining 54 patients (Group II-a). On the other hand, of the 54 patients in Group II-a, stress-induced cardiomyopathy was noted in 15 and myocarditis in 8. LVEF (53.3±13.8% vs. 59.2±13.0%, p=0.014) and creatinine clearance (71.3±33.0 vs. 89.4±32.6 ml/min, p=0.009) were lower, and the levels of NT-proBNP (4,804±7,658 vs. 1,417±3,314 pg/ml, p=0.008) and hs-CRP (3.5±6.8 vs. 0.9±1.3 mg/dl, p=0.023) were higher, in Group II-a than in Group II-b (Tables 3, 4).

3. Etiologic factors tended to elevate cardiac biomarkers without ischemic injury in Group II

Of 100 patients, 7 (7%) had anemia (Hgb < 8 mg/dl), 2 (2%) had severe aortic stenosis, and 3 (3%) had chronic kid-...
TABLE 3. Baseline clinical characteristics in acute myocardial infarction patients without significant coronary stenosis and without (Group II-a) or with (Group II-b) possible etiologies

| Group II-a (n=54) | Group II-b (n=46) | p value |
|------------------|------------------|---------|
| Age (yrs)        | 60.7±15.0        | 5.9±12.8 | 0.089  |
| Male gender (%)  | 67.4             | 51.9    | 0.170  |
| SBP (mm Hg)      | 131.1±32.9       | 126.5±32.8 | 0.494  |
| LVEF (%)         | 53.3±13.8        | 59.2±13.0 | 0.014  |
| Risk factors     |                  |         |         |
| HTN              | 19 (35.2)        | 22 (47.8) | 0.281  |
| DM               | 7 (13.0)         | 3 (6.5)  | 0.462  |
| Smoking          | 22 (40.7)        | 27 (58.7) | 0.112  |
| Hyperlipidemia   | 1 (1.9)          | 0 (0)    | 1.000  |
| Family history   | 5 (9.3)          | 7 (15.2) | 0.545  |

Values are presented as number (%) or means±SD. SBP: systolic blood pressure, LVEF: left ventricular ejection fraction, HTN: hypertension, DM: diabetes mellitus.

TABLE 4. Laboratory findings in acute myocardial infarction patients without significant stenosis on a coronary angiogram and with (Group II-b) or without (Group II-a) possible etiology

| Glucose (mg/dl) | 168.9±95.6 | 152.6±76.1 | 0.344 |
|-----------------|------------|------------|-------|
| Creatinine clearance (ml/min) | 71.3±33.0 | 89.4±32.5 | 0.009 |
| Creatine kinase (U/L) | 830±1,476 | 731±1,042 | 0.696 |
| CK-MB (U/L) | 37.9±61.5 | 39.1±43.2 | 0.910 |
| Troponin I (ng/ml) | 16.1±33.2 | 17.1±26.6 | 0.860 |
| Total cholesterol (mg/dl) | 163.5±44.3 | 171.1±38.2 | 0.813 |
| HDL cholesterol (mg/dl) | 49.0±16.8 | 50.9±17.2 | 0.585 |
| LDL cholesterol (mg/dl) | 99.5±35.7 | 106.1±30.8 | 0.349 |
| hs-CRP (mg/dl) | 3.5±6.8 | 3.8±7.4 | 0.233 |
| NT-proBNP (pg/ml) | 4,804±7,658 | 1,417±3,314 | 0.008 |
| Apo-B/A1 | 0.71±0.2 | 0.69±0.2 | 0.780 |
| Lp (a) (mg/dl) | 27.9±25.3 | 20.6±12.2 | 0.120 |

Values are presented as means±SD. CK-MB: muscle brain isoenzyme of creatine kinase, HDL cholesterol: high-density lipoprotein cholesterol, LDL cholesterol: low-density lipoprotein cholesterol, hs-CRP: high-sensitivity C-reactive protein, NT-proBNP: N-terminal pro-brain natriuretic peptide, Apo-B/A1: the ratio of apolipoprotein-B to -A1, Lp (a): lipoprotein (a).

TABLE 5. Medications at hospital discharge in acute myocardial infarction patients with (Group I) or without (Group II) significant coronary artery stenosis on an angiogram

|                     | Group I (n=120) | Group II (n=100) | p value |
|---------------------|-----------------|------------------|---------|
| Aspirin             | 52 (93.9)       | 73 (73.0)        | <0.001  |
| Clopidogrel         | 1,031 (92.1)    | 24 (24.0)        | <0.001  |
| Beta-blocker        | 904 (80.7)      | 25 (25.0)        | <0.001  |
| Calcium channel blocker | 71 (6.3)   | 48 (48.0)        | <0.001  |
| Diuretics           | 215 (19.2)      | 24 (24)          | 0.239   |
| ACE inhibitors      | 831 (74.2)      | 41 (41.0)        | <0.001  |
| Statin              | 835 (74.6)      | 52 (52.0)        | <0.001  |

Values are presented as number (%). ACE inhibitors: angiotensin-converting enzyme inhibitors.

TABLE 6. Adjusted odds ratios for discharge medications of 1-year major adverse cardiac events in all patients of both groups

| Medication          | aOR   | 95% CI     | p value |
|---------------------|-------|------------|---------|
| No prior aspirin    | 7.099 | (3.446-14.623) | <0.001 |
| No prior clopidogrel| 0.670 | (0.353-1.271) | 0.220   |
| No prior beta-blocker | 1.233 | (0.829-1.835) | 0.301   |
| No prior calcium blocker | 2.113 | (1.233-3.622) | 0.006   |
| No prior diuretics  | 0.703 | (0.497-0.995) | 0.047   |
| No prior ACE inhibitors | 2.009 | (1.444-2.795) | <0.001 |
| No prior statin     | 1.394 | (0.997-1.950) | 0.052   |

aOR: adjusted odds ratio, CI: confidence interval, ACE inhibitors: angiotensin-converting enzyme inhibitors.

5. Major adverse cardiac events and all-cause mortality

LVEF (<40%), creatinine clearance (<60 ml/min), hs-CRP (>2 mg/dl), NT-proBNP (>500 pg/ml), and medications (ACEi or ARB) were associated with 1-year MACE in the combined Group I and Group II (Table 7). Clinical outcomes at 1 month and 12 months after the onset of AMI in Group I and Group II are presented in Table 8 and Fig. 1. The 1-year follow up rate was 99.7%. The cumulative MACE rate was 5.0% at 1 month and 9% at 12 months in Group II. The MACE rate did not differ significantly between Groups I and II. Outcomes including mortality and 12-month MACE were also similar between Group II-a and Group II-b (Table 9). Kaplan-Meier death and myocardial infarction-free survival curves up to 1 year revealed a similar survival rate in the two groups (96.0 vs. 97.4%, p > 0.05) (Fig. 1).
In addition, our study showed that the out-

comings of the patients in Group II were similar to those of

Group I patients during the 1-year follow-up, although the

patients in the former group were younger, were less likely
to have cardiovascular disease risk factors, and had lower

heart enzymes. Groups II-a and II-b also showed a sim-

eral 1-year outcome, although the former had a higher level

of NT-proBNP and hs-CRP and a lower LVEF than did the

**TABLE 7. Multivariable risk factors of 1-year major adverse card-

iac events in all acute myocardial infarction patients both with

and without significant coronary artery stenosis (n=1,220)**

| Multivariable predictors | OR     | 95% Cl      | p value |
|--------------------------|--------|-------------|---------|
| Elderly (>65 years)      | 1.305  | 0.696-2.450 | 0.407   |
| Male gender              | 0.942  | 0.472-1.883 | 0.867   |
| CVD                      | 2.032  | 0.951-4.339 | 0.067   |
| Complications (shock, VT) | 2.089  | 1.230-3.549 | 0.006   |
| LVEF (<40%)              | 2.286  | 1.374-3.803 | <0.001  |
| Glucose (<200 mg/dl)     | 0.673  | 0.373-1.213 | 0.188   |
| Creatinine clearance (<60 ml/min) | 2.599  | 1.410-4.790 | 0.002   |
| hs-CRP (>2 mg/dl)        | 1.825  | 1.124-2.964 | 0.015   |
| NT-proBNP (>500 pg/ml)   | 2.295  | 1.186-4.444 | 0.014   |
| Medication (cilostazol)  | 0.708  | 0.425-1.181 | 0.186   |
| Medication (β-blocker)   | 0.943  | 0.513-1.735 | 0.851   |
| Medication (ACEi or ARB) | 0.422  | 0.231-0.770 | 0.005   |
| Injection (LMWH)         | 1.184  | 0.721-1.945 | 0.505   |

OR: odds ratio, Cl: confidence interval, CVD: coronary vascular dis-

ease, VT: ventricular tachycardia, LVEF: left ventricular ejection

fraction, hs-CRP: high-sensitivity C-reactive protein, NT-proBNP: N-
terminal pro-brain natriuretic peptide, ACEi: angiotensin-con-

verting enzyme inhibitor, ARB: angiotensin II receptor blocker,

LMWH: low molecular weight heparin.

**TABLE 8. Major adverse cardiac events (MACE) at 1 month and

12 months in all patients with acute myocardial infarction with

(Group I) or without (Group II) significant coronary stenosis**

|                  | Group I (n=1,120) | Group II (n=100) | p value |
|------------------|-------------------|------------------|---------|
| One-month        |                   |                  |         |
| MACE             | 91 (8.5)          | 5 (5.0)          | 0.345   |
| Cardiac death    | 74 (6.6)          | 4 (4.0)          | 0.427   |
| Noncardiac death | 9 (0.8)           | 1 (1.0)          | 1.000   |
| Reinfarction     | 8 (0.7)           | 0 (0.0)          | 0.844   |
| 12-months        |                   |                  |         |
| MACE             | 126 (11.3)        | 9 (9.0)          | 0.503   |
| Cardiac death    | 94 (8.4)          | 4 (4.0)          | 0.179   |
| Noncardiac death | 27 (2.4)          | 3 (3.0)          | 0.971   |
| Reinfarction     | 5 (0.4)           | 2 (2.0)          | 0.198   |

Values are presented as number (%).

**TABLE 9. Major adverse cardiac events (MACE) at 1 month and

12 months in acute myocardial infarction patients without sig-

nificant coronary stenosis and with (Group II-a) or without (Group

II-b) possible etiologies**

|                  | Group II-a (n=54) | Group II-b (n=46) | p value |
|------------------|-------------------|-------------------|---------|
| One-month        |                   |                   |         |
| MACE             | 4 (7.4)           | 1 (2.2)           | 0.217   |
| Cardiac death    | 3 (5.6)           | 1 (2.2)           | 0.744   |
| Noncardiac death | 1 (1.9)           | 0 (0.0)           | 1.000   |
| Reinfarction     | 0 (0.0)           | 0 (0.0)           | 1.000   |
| 12-months        |                   |                   |         |
| MACE             | 6 (11.1)          | 3 (6.7)           | 0.678   |
| Cardiac death    | 3 (5.6)           | 1 (2.2)           | 0.744   |
| Noncardiac death | 2 (3.7)           | 1 (2.2)           | 1.000   |
| Reinfarction     | 1 (1.9)           | 1 (2.2)           | 1.000   |

Values are presented as number (%).

**FIG. 1. Kaplan-Meir plots of cumulative death or myocardial infarction-free survival for patients with acute myocardial infarction with (Group I, n=1,120) or without (Group II, n=100) significant coronary stenosis.** There was a trend for a lower incidence of death or myocardial infarction in Group II than in Group I during 1 year of clinical follow-up (p=0.096).

**DISCUSSION**

The present study demonstrated that the prevalence of MINC, defined as a cutoff stenosis limit of 50%, was approxi-

mately 8.2% in patients who underwent coronary angiog-

raphy for indication of AMI. This finding is consistent with

prevalences ranging from 1% to 12% of AMI patients, de-

pending on the definition of normal coronary arteries used,

i.e., “without any endoluminal irregularity” or “no sig-

nificant stenosis (<50% stenosis),” in previous investi-

gations.12,17 In addition, our study showed that the out-

comes of the patients in Group II were similar to those of

Group I patients during the 1-year follow-up, although the

patients in the former group were younger, were less likely
to have cardiovascular disease risk factors, and had lower

heart enzymes. Groups II-a and II-b also showed a sim-

eral 1-year outcome, although the former had a higher level

of NT-proBNP and hs-CRP and a lower LVEF than did the

latter.

Most previous studies have demonstrated that MINC patients have lower cardiovascular disease risk profiles and heart enzymes than do MICAS patients, whereas others did not find a difference.12,21-24 We also found that Group II patients were less likely to have cardiovascular disease risk profiles (i.e., diabetes mellitus, smoking, and LDL-cholesterol levels), except for family history, were more likely to be women, and had lower tropo-
nin I and CK-MB levels than did the Group I patients. However, AMI patients with near-normal coronary angiograms in our study tended to be older (mean age 58.5±14.2 years) than were those with near-normal coronary arteries in previous studies, in which age ranged from 42 to 47 years.

Several potential etiologies or mechanisms underlying the occurrence of AMI in patients with near-normal coronary angiograms have been proposed, including concealed atherosclerosis, coronary spasm, thrombosis and hypercoagulability, embolisation, and inflammation, although the eventual etiology remains uncertain in the majority of patients. To determine whether the clinical characteristics and prognosis differed according to the underlying mechanisms, in the present study, we further classified the MINC cohort into 2 subgroups according to their causative pathology: Group II-a (cryptogenic) and Group II-b (with possible etiologies). Our data showed that the possible causative factors in Group II patients were coronary spasm (29%), myocardial infarcts (11%), and spontaneous thrombosis (6%), whereas the causative factors were uncertain in 54% of cases (Group II-a).

We also found that the clinical outcomes of Groups II-a were similar to those of Group II-b; however, serum hs-CRP levels were significantly higher in the former group than in the latter. There is currently abundant evidence linking inflammation with cardiovascular diseases. hs-CRP is a maker of inflammation that predicts cardiovascular events among healthy individuals. In addition, a previous study demonstrated that MINC patients, as compared with MICAS patients, had more frequent febrile infections, mainly of the upper airways, within 2 weeks before AMI, and had a higher seroprevalence of antibodies for Helicobacter pylori, Chlamydia pneumonia, and cytomegalovirus, compatible with an inflammatory component of AMI. Moreover, 8 (14.8%) of 54 patients in Group II-a had myocarditis in the present study. Therefore, our finding of increased hs-CRP levels in Group II-a support the previous notion that inflammation may play a role in the pathogenesis of MINC or at least in part contributes to its pathogenesis, although the prevalence of infections was not evaluated in the present study.

NT-proBNP levels were also higher in the Group II-a subgroup. NT-pro-BNP, a cleavage remnant of BNP, is synthesized and secreted by the ventricular myocardium in response to increases in volume or pressure and is known as a predictor of heart failure. It has a longer half-life than BNP and is renally cleared, thus making it susceptible to significant changes based on alterations in renal function. The increased NT-proBNP level in Group II-a may have been attributed to a reduced left ventricular function, as evidenced by the reduced LVEF, or to decreased renal clearance, as evidenced by the reduced creatinine clearance rate. Indeed, in the present study, 15 (27.8%) of 54 patients in Group II-a had stress-induced cardiomyopathy, which is reported to be associated with marked and persistent elevation of NT-proBNP/BNP levels.

Although there is general agreement that cardiovascular risk and cardiac enzymes are lower in AMI patients with near-normal angiographic findings, the prognosis of these patients is the subject of some debate. Kang et al. studied 3,056 patients, of whom 126 (4.4%) had near-normal coronary arteries, and observed a MACE rate including death and reinfarction of 7.8% during 1 year of follow-up in MINC patients vs. 12.2% in comparators with one- or two-vessel disease (p=0.359). Similarly, Group II patients in our study experienced a MACE rate of approximately 9.0% compared with 11.3% in Group I patients (p=0.503) in the first year. Cardiac deaths in 4 patients (4.0%) and noncardiac deaths in 3 patients (3.0%) were the most frequent events in Group II during this follow-up period. These findings indicate that AMI patients with near-normal coronary angiograms experience a significant adverse cardiac event rate and show an overall outcome that is similar to that of MICAS patients within 1 year. However, it has been reported that different degrees of coronary involvement among patients with MINC (a culprit lesion causing <50% angiographic luminal narrowing) show different prognoses, with very few ischemic events in those having strictly normal vessels at long-term follow-up. Indeed, the prevalence of MINC has fallen to about 1% with advanced diagnostic technologies such as intravascular sonography, multislice computed tomography, and magnetic resonance imaging, and consequently these patients are associated with excellent prognosis. Therefore, it is likely that the prognosis of MINC patients may differ depending on the definition of MINC with different diagnostic procedures, and those with an absolutely normal coronary artery have a better long-term prognosis than do patients with obstructive coronary artery disease. Nevertheless, the combined morbidity and mortality are not negligible, and thus close follow-up and strict secondary prevention measures, including smoking cessation and prevention of dyslipidemia and diabetes, may be needed in this subset of patients.

The present study had several limitations. First, the data in the present study were retrospectively analyzed in a single center. Angiographic data were harvested from reports available in the cardiac catheterization laboratory database and were largely based on operator description are subject to interobserver descriptive variability. Follow-up data were gleaned from electronic records and in part were obtained by telephone; the accompanying limitations in terms of reliability and accuracy are acknowledged. However, this uncommon condition does not lend itself to randomization and thus charts and angiograms were reviewed. Second, patients in Group I (≥50% stenosis) were not further stratified in the present study on the basis of the severity of CAD or the number of vessels involved. Long-term clinical outcomes may differ with different stratification in MICAS and even in MINC. Third, the time intervals between the onset of chest symptoms and percutaneous coronary intervention were not the same, and the use of thrombolytic therapy before the angiography.
was not evaluated. The longer the time interval, the more frequently a thrombotic occlusion would have been resolved before catheterization was done, thus resulting in a shift from the MICAS to the MINC group. Fourth, the provocative ergonovine test was not performed in all patients, and the lack of structured workup for hypercoagulable states also limited the ability to systematically analyze the data for etiological factors in Group II. Finally, the small number of patients in Group II and the relatively short duration of follow-up (12 months) might have precluded our ability to detect differences between the groups. Further studies involving a larger number of patients and long-term outcome are needed.

In conclusion, the present study demonstrated that AMI patients with near-normal coronary arteries by angiography have clinical outcomes and prognosis similar to those of AMI patients with occlusive CAD. In addition, 1-year outcomes appear to be similar between MINC patients without and with possible etiologic factors such as coronary spasm, myocardial bridges, and transient thrombosis.

ACKNOWLEDGEMENTS

This work was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health, Welfare & Family Affairs, Republic of Korea (A084869).

REFERENCES

1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:356-72.
2. Legrand V, Deliege M, Henrand L, Boland J, Kulbertus H. Patients with myocardial infarction and normal coronary arteriogram. Chest 1982;82:678-85.
3. Negus BH, Willard JE, Glamann DB, Snyder RW 2nd, Hillis LD, et al. Coronary anatomy and prognosis of young, asymptomatic survivors of myocardial infarction. Am J Med 1994;96:354-8.
4. Kardasz I, De Caterina R. Myocardial infarction with normal coronary arteries: a conundrum with multiple aetiologies and variable prognosis: an update. J Int Med 2007;261:330-48.
5. Fuster V, Chesebro JH, Frye RL, Elleback LR. Platelet survival and the development of coronary artery disease in the young adult: effects of cigarette smoking, strong family history and medical therapy. Circulation 1981;63:546-51.
6. Ross R, Kay R, Ambrose J, Herman MV. Coronary thrombosis in the absence of angiographically-evident obstructive coronary disease. Chest 1983;84:768-70.
7. Steele P, Rainwater J, Vogel R. Abnormal platelet survival time in men with myocardial infarction and normal coronary arteriogram. Am J Cardiol 1978;41:60-2.
8. Gersh BJ, Bassendine MF, Forman R, Walls RS, Beck W. Coronary artery spasm and myocardial infarction in the absence of angiographically demonstrable obstructive coronary disease. Mayo Clin Proc 1981;56:700-8.
9. Glazier JJ, McGinnity JG, Spears JR. Coronary embolism complicating aortic valve endocarditis: treatment with placement of an intracoronary stent. Clin Cardiol 1997;20:885-8.
10. Granger EK, Rankin J, Labarlestier RI, Hockings BE. Obstruction of the right coronary artery ostium by an aortic valve papillary fibroelastoma. Heart Lung Circ 2005;14:266-8.
11. Rigatelli G. Normal angiogram in patients with acute coronary syndrome: searching for unusual substrates of myocardial ischemia. Int J Cardiol 2005;99:25-7.
12. Alpert JS. Myocardial infarction with angiographically normal coronary arteries. Arch Intern Med 1994;154:265-9.
13. Proudfoot WL, Brauschke VG, Sones FM Jr. Clinical course of patients with normal or slightly or moderately abnormal coronary arteriograms: 10-year follow-up of 521 patients. Circulation 1980;62:712-7.
14. Terefe YG, Niraj A, Pradhan J, Kondur A, Afonso L. Myocardial infarction with angiographically normal coronary arteries in the contemporary era. Coron Artery Dis 2007;18:621-6.
15. Bounhoure JP, Ouldzen H, Carrié D, Alibelli MJ, Puel J. Myocardial infarction with "angiographically normal coronary arteries" myth or reality?. Bull Acad Natl Med 2007;191:815-24.
16. Raymond R, Lynch J, Underwood D, Leatherman J, Razavi M. Myocardial infarction and normal coronary arteriography: a 10 year clinical and risk analysis of 74 patients. J Am Coll Cardiol 1988;11:471-7.
17. Larsen AI, Galbraith PD, Ghali WA, Norris CM, Graham MM, Knudtson ML; APPROACH Investigators. Characteristics and outcomes of patients with acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol 2005;95:261-3.
18. Kang WY, Jeong MH, Ahn YK, Kim JH, Chae SC, Kim YJ, et al; Korea Acute Myocardial Infarction Registry Investigators. Are patients with angiographically near-normal coronary arteries who present as acute myocardial infarction actually safe? Int J Cardiol 2011;146:207-12.
19. Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med 2006;166:1391-5.
20. French JK, White HD. Clinical implications of the new definition of myocardial infarction. Heart 2004;90:99-106.
21. Raymond R, Lynch J, Underwood D, Leatherman J, Razavi M. Myocardial infarction and normal coronary arteriography: a 10 year clinical and risk analysis of 74 patients. J Am Coll Cardiol 1988;11:471-7.
22. Fournier JA, Sánchez-González A, Quero J, Cortacero JA, Caballo A, Revello A, et al. Normal angiogram after myocardial infarction in young patients: a prospective clinical-angiographic and long-term follow-up study. Int J Cardiol 1997;60:281-7.
23. Da Costa A, Isaaz K, Faure E, Mourot S, Cerisier A, Lamaud M. Clinical characteristics, aetiological factors and long-term prognosis of myocardial infarction with an absolutely normal coronary angiogram; a 3-year follow-up study of 91 patients. Eur Heart J 2001;22:1459-65.
24. Golzio PG, Orzan F, Ferrero P, Bobbio M, Bergerone S, Di Leo M, et al. Myocardial infarction with normal coronary arteries: ten-year follow-up. Ital Heart J 2004;5:732-8.
25. Brecker SJ, Stevenson RN, Roberts R, Uthayakumar S, Timmis AD, Balcon R. Acute myocardial infarction in patients with normal coronary arteries. BMJ 1993;307:1255-6.
26. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med 1999;340:115-26.
27. Yun KH, Oh SK, Park EM, Kim HJ, Shin SH, Lee EM, et al. An increased monocyte count predicts coronary artery spasm in patients with resting chest pain and insignificant coronary artery stenosis. Korean J Intern Med 2006;21:97-102.
28. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004;29:439-93.
29. Ammann P, Marschall S, Kraus M, Schmid L, Angehrn W, Krapf R, et al. Characteristics and prognosis of myocardial infarction in patients with normal coronary arteries. Chest 2000;117:333-8.
30. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921-9.
31. Nguyen TH, Neil CJ, Sverdlov AL, Mahadavan G, Chirkov YY, Kucia AM, et al. N-terminal pro-brain natriuretic protein levels in takotsubo cardiomyopathy. Am J Cardiol 2011;108:1316-21.
32. Abdulla J, Asferg C, KofodKF. Prognostic value of absence or presence of coronary artery disease determined by 64-slice computed tomography coronary angiography a systematic review and meta-analysis. Int J Cardiavasc Imaging 2011;27:413-20.